Police & Firemen s Retirement System of New Jersey Grows Position in GeneDx Holdings Corp. $WGS

Police & Firemen s Retirement System of New Jersey grew its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 60.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,261 shares of the company's stock after acquiring an additional 1,608 shares during the quarter. Police & Firemen s Retirement System of New Jersey's holdings in GeneDx were worth $393,000 at the end of the most recent quarter.

• Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

A number of other large investors have also made changes to their positions in WGS. Geode Capital Management LLC increased its position in GeneDx by 23.4% during the 2nd quarter. Geode Capital Management LLC now owns 484,714 shares of the company's stock worth $44,750,000 after purchasing an additional 91,989 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of GeneDx by 143.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,612 shares of the company's stock worth $333,000 after purchasing an additional 2,127 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of GeneDx during the 2nd quarter worth about $5,234,000. ProShare Advisors LLC grew its holdings in shares of GeneDx by 39.1% during the second quarter. ProShare Advisors LLC now owns 3,850 shares of the company's stock worth $355,000 after buying an additional 1,083 shares in the last quarter. Finally, Lisanti Capital Growth LLC grew its holdings in shares of GeneDx by 92.3% during the second quarter. Lisanti Capital Growth LLC now owns 56,615 shares of the company's stock worth $5,226,000 after buying an additional 27,180 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Trading Up 4.0%

WGS stock opened at $167.51 on Wednesday. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. The company has a market cap of $4.84 billion, a price-to-earnings ratio of 1,861.22 and a beta of 2.01. The business has a fifty day simple moving average of $128.56 and a 200-day simple moving average of $105.58. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $167.72.

• GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.21. The firm had revenue of $116.74 million for the quarter, compared to analysts' expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. GeneDx has set its FY 2025 guidance at EPS. On average, equities research analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on WGS. BTIG Research upped their price objective on shares of GeneDx from $140.00 to $165.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. Weiss Ratings reissued a "sell (d)" rating on shares of GeneDx in a research note on Wednesday, October 8th. Canaccord Genuity Group set a $160.00 price objective on GeneDx and gave the stock a "buy" rating in a report on Wednesday, October 29th. Piper Sandler upped their target price on GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, September 11th. Finally, Zacks Research lowered GeneDx from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 2nd. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeneDx currently has an average rating of "Moderate Buy" and a consensus target price of $129.22.

Read Our Latest Report on WGS

Insider Activity

In related news, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $452,840.16. Following the transaction, the chief financial officer owned 8,755 shares in the company, valued at approximately $1,063,469.85. This trade represents a 29.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the transaction, the chief executive officer directly owned 14,578 shares in the company, valued at approximately $1,770,789.66. This trade represents a 41.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 17,153 shares of company stock worth $2,123,584 over the last ninety days. Corporate insiders own 29.60% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Read More

• Five stocks we like better than GeneDx
• ETF Screener: Uses and Step-by-Step Guide
• Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
• How to Invest in Biotech Stocks
• From Science Project to Solvent: WeRide’s 761% Revenue Surge
• How to Start Investing in Real Estate
• Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here